US drug and antitrust regulators have signalled their intent to crack down on anti-competitive behaviour in the biologics and biosimilar industries, in an effort to bring down prices.
The AARP has urged the US Court of Appeals for the Ninth Circuit to uphold a newly-formed California law prohibiting the majority of pay-for-delay pharmaceutical settlements.
A Virginia judge has approved Par Pharmaceutical’s settlement with a group of direct purchasers, allowing the pharmaceutical company to escape a pay-for-delay lawsuit.
EU authorities seized €7.9 million worth of counterfeit medicines—including fake cancer drugs, antivirals, and erectile dysfunction medicines—as part of an operation carried out last year.
Drugmakers including Gilead Sciences must face antitrust claims related to HIV drugs, after the US District Court for the District of Florida on Monday, March 3 refused to fully throw out a class-action suit implicating the company.
Cooley has grown its IP litigation practice with the addition of partners Sanya Sukduang and Jonathan Davies, who will be based in Washington, DC.
Biotech company Bioverativ has accused CSL Behring of infringing three patents covering its haemophilia B treatment Alprolix.
India has imposed export restrictions on drugs and active pharmaceutical ingredients (APIs), including paracetamol, amid fears over COVID-19-related shortages.
Biotech Thermo Fisher Scientific has announced plans to acquire Dutch diagnostics group Qiagen for $11.5 billion.
April Weisbruch has joined McDermott Will & Emery as an IP partner, moving from Sheppard Mullin Richter & Hampton, where she worked as an IP associate.